Browse drugs

…state health sector in which several novel cancer drugs such as osimertinib, alectinib and immunotherapy are not approved for use in advanc…

…ducted, no agents have received approval, with the exception of valrubicin, largely attributed to factors such as the varied prior BCG exp…

… therapeutic positioning.Aim and Objectives To evaluate whether pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezoli…

…minantly stereotactic radiosurgery (SRS)) followed by continued osimertinib, with encouraging PFS/OS and acceptable toxicity. By contrast, …

…l lung cancer (ES-SCLC) provides only modest survival benefits. Tislelizumab has been recently approved by the European Commission, but head…

…tage III NSCLC who were treated with chemoradiation followed by durvalumab. Data collection included baseline characteristics, treatment p…

…erapy –specifically those including pembrolizumab, dostarlimab, durvalumab, durvalumab plus olaparib, and atezolizumab–, in the treatment …

…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…

… inhibitor olaparib in combination with the anti-PD-L1 antibody durvalumab in an HRR-unselected population of men with metastatic castrati…

…s In 06/2025, the patient began treatment with tremelimumab and durvalumab. Three weeks after the first cycle he developped cough and desa…

…ring may help identify patients who could benefit from extended osimertinib therapy, although further clinical validation is warranted.ctDN…

…otherapy, 563 (87.4%) received atezolizumab; 61 (9.5%) received durvalumab. We found that the median OS was 9 months vs 7.2 months (p <0.0…